Recruitment

Recruitment Status
Completed
Estimated Enrollment
250

Inclusion Criteria

between 1.1 and 1.5 cm in the longest dimension and greater than 1.0 cm in the shortest axis
greater than 1.5 cm in the longest dimension or
Patient has confirmed CD20+ lymphoma, as assessed by local laboratory review. (Tissue obtained within 6 months before Day 1 of Cycle 1 will be reviewed by a central independent reviewer to detect pathological type.)
...
between 1.1 and 1.5 cm in the longest dimension and greater than 1.0 cm in the shortest axis
greater than 1.5 cm in the longest dimension or
Patient has confirmed CD20+ lymphoma, as assessed by local laboratory review. (Tissue obtained within 6 months before Day 1 of Cycle 1 will be reviewed by a central independent reviewer to detect pathological type.)
Patient has histologically confirmed FL according to the World Health Organization 2008 classification (Jaffe 2009); grades 1 to 3a based on local laboratory review.
Patient has Ann Arbor stage III or IV disease.
Patient is male or female older than 18 years.

Exclusion Criteria

Patient has allergies or hypersensitivity to murine, chimeric, human or humanised proteins, cyclophosphamide, vincristine, or prednisone.
Previous treatment including chemotherapy, radiotherapy, immunotherapy, and/or surgery (except previous biopsy)
Patient has evidence of histological transformation to high-grade or diffuse large B-cell lymphoma.
...
Patient has allergies or hypersensitivity to murine, chimeric, human or humanised proteins, cyclophosphamide, vincristine, or prednisone.
Previous treatment including chemotherapy, radiotherapy, immunotherapy, and/or surgery (except previous biopsy)
Patient has evidence of histological transformation to high-grade or diffuse large B-cell lymphoma.
Patient has known central nervous system involvement.
All doses of corticoid therapy for treatment of NHL
Corticoid therapy during the previous 4 weeks from Day 1 of Cycle 1 with prednisone >20 mg per day for the treatment for any purpose
Patient has received rituximab (or a rituximab biosimilar), cyclophosphamide, or vincristine.

Summary

Conditions
Lymphoma, Follicular
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

between 1.1 and 1.5 cm in the longest dimension and greater than 1.0 cm in the shortest axis
greater than 1.5 cm in the longest dimension or
Patient has confirmed CD20+ lymphoma, as assessed by local laboratory review. (Tissue obtained within 6 months before Day 1 of Cycle 1 will be reviewed by a central independent reviewer to detect pathological type.)
...
between 1.1 and 1.5 cm in the longest dimension and greater than 1.0 cm in the shortest axis
greater than 1.5 cm in the longest dimension or
Patient has confirmed CD20+ lymphoma, as assessed by local laboratory review. (Tissue obtained within 6 months before Day 1 of Cycle 1 will be reviewed by a central independent reviewer to detect pathological type.)
Patient has histologically confirmed FL according to the World Health Organization 2008 classification (Jaffe 2009); grades 1 to 3a based on local laboratory review.
Patient has Ann Arbor stage III or IV disease.
Patient is male or female older than 18 years.

Exclusion Criteria

Patient has allergies or hypersensitivity to murine, chimeric, human or humanised proteins, cyclophosphamide, vincristine, or prednisone.
Previous treatment including chemotherapy, radiotherapy, immunotherapy, and/or surgery (except previous biopsy)
Patient has evidence of histological transformation to high-grade or diffuse large B-cell lymphoma.
...
Patient has allergies or hypersensitivity to murine, chimeric, human or humanised proteins, cyclophosphamide, vincristine, or prednisone.
Previous treatment including chemotherapy, radiotherapy, immunotherapy, and/or surgery (except previous biopsy)
Patient has evidence of histological transformation to high-grade or diffuse large B-cell lymphoma.
Patient has known central nervous system involvement.
All doses of corticoid therapy for treatment of NHL
Corticoid therapy during the previous 4 weeks from Day 1 of Cycle 1 with prednisone >20 mg per day for the treatment for any purpose
Patient has received rituximab (or a rituximab biosimilar), cyclophosphamide, or vincristine.

Tracking Information

NCT #
NCT02162771
Collaborators
Not Provided
Investigators
Not Provided
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2023